BioCryst Pharmaceuticals, Inc. (BCRX) Stock: A Biotechnology Stock That’s Seeing Declines

0

BioCryst Pharmaceuticals, Inc. (BCRX) is working its way for to the bottom in the market in today’s trading session. The company, one that is focused in the biotech space, is presently trading at $2.11 after tumbling -8.48% so far today. As it relates to biotech stocks, there are several aspects that have the potential to cause declines in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent trending headlines centered around BCRX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-30-19 10:33AM Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for
Oct-29-19 10:32AM Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for
07:00AM BioCryst to Provide Commercial Update and Report Third Quarter 2019 Financial Results on November 6
Oct-28-19 06:59AM BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients
Oct-03-19 07:00AM BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nonetheless, any time investors are making a decision with regard to investing, investors should look into far more than just news, this is especially the case in the highly speculative biotechnology industry. Here’s what’s happing when it comes to BioCryst Pharmaceuticals, Inc..

What We’ve Seen From BCRX

Although a move down on a single session, like the fall that we’re seeing from BioCryst Pharmaceuticals, Inc. may make some investors fearful, a single session move alone shouldn’t be the reason for a decision to, or not to, invest in a company. It is always smart to take a look at trends just a single trading session. As it relates to BCRX, here are the returns on investment that we have seen:

  • Weekly – Throughout the last five trading sessions, BCRX has seen a price change in the amount of -3.36%.
  • Past 30 Days – The return from BioCryst Pharmaceuticals, Inc. over the past 30 days works out to -19.72%.
  • Quarterly – In the past three months, the company has generated a ROI of -27.44%
  • Past 6 Months – In the last six months, we have seen a performance that amounts to -68.41% from the company.
  • Year To Date – Since the the last trading session of last year BCRX has generated a return on investment of -71.50%.
  • Full Year – Finally, throughout the past year, investors have seen performance amounting to -67.92% out of BCRX. In this period, the stock has traded at a high of -78.84% and a low of -6.44%.

Crucial Ratios

Digging into a few ratios having to do with a stock can provide prospective investors a look of how dangerous and/or rewarding a an investment option might be. Below are some of the key ratios to consider when digging into BCRX.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors are expecting that the stock is headed for declines. Across the sector, biotechnology stocks can carry a higher short ratio. However, we also tend to see quite a few short squeezes in the sector. Nonetheless, in relation to BioCryst Pharmaceuticals, Inc., it’s short ratio comes to 9.51.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure the company’s abilities to pay its debts when they come due with only current assets or quick assets. In the biotech industry, many companies are heavily reliant on continued investor support, the current and quick ratios can be upsetting. Nonetheless, quite a few gems in the biotech industry come with great quick and current ratios. When it comes to BCRX, the quick and current ratios add up to 1.40 and 1.40 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets owned by the company to the price of shares. In the case of BioCryst Pharmaceuticals, Inc., that ratio is -0.08.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the value of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotech industry, this is a very important ratio to consider. As it relates to BCRX, the cash to share value ratio works out to 0.83.

What Analysts Think About BioCryst Pharmaceuticals, Inc.

Although it’s never a smart idea to unknowingly follow the opinions of analysts, it is a good idea to consider their analysis in order to validate your own due diligence when it comes to making investment decisions in the biotechnology space. Below are the recent moves that we’ve seen from analysts when it comes to BCRX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-24-19 Downgrade RBC Capital Mkts Outperform → Sector Perform $16 → $4.50
Nov-16-18 Resumed Piper Jaffray Overweight $15
Aug-08-18 Resumed JP Morgan Overweight $9
Jul-17-18 Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18 Initiated Seaport Global Securities Neutral

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in BCRX, here’s what we’re seeing:

  • Institutions – At the moment, institutions own 95.00% of BCRX. Nonetheless, it’s worth mentioning that institutional ownership has seen a move of 2.53% throughout the past quarter.
  • Insider Moves – as it relates to insiders, members of the management team and others close to BCRX currently own 0.20% of the company. Insider ownership of the company has seen a move of -19.87% over the last 3 months.

How Many Shares Of BCRX Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 110.43M shares of BioCryst Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, BCRX has a float of 109.30M.

I also find it important to pay attention to the short percentage of the float. Think about it, when a high portion of the float is sold short, the overall opinion in the market is that the company is going to take a dive. As far as BCRX, the percentage of the float that is currently being sold short sits at 12.75%. Most traders believe that a concerning short percent of the float is any percentage over 40%. Nonetheless, I’ve found that any short ratio over 26% is probably going to be a risky play.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.03. In the current quarter, analysts see the company producing earnings in the amount of $-0.32. Over the last 5 years, BCRX has generated revenue in the amount of $3.60% with earnings coming in at -12.50%. On a quarter over quarter basis, earnings have seen movement of -82.60% and revenue has seen movement of -88.80%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I am very dependent on human beings. A human built me! Although, my creators made it possible for me to learn on my own, it is a lot simpler to learn when I receive human feedback. At the bottom of this article, you will find a comment section. If you would like for me dig into other data, tweak the way in which provide data, look at data from an alternative angle, or if you’d like to tell me anything else, I’d love to know. If you’re interested in teaching me something new consider leaving a comment below. I will read that comment and it will help me become a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here